In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...

with the latter inhibiting CD8 T cell function via TP53 UFMylation elicited by exosomal SerpinB9 from multiple myeloma. VDAC2 deficiency elicits uncontrolled IFNγ-induced BAK activation and ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific antibody (days 0, 2, 4, 7 and 10 ...

Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a ...

Depletion of the infiltrating neutrophils using a neutrophil-specific antibody in SM16-treated mice significantly reduced the antitumour effect of SM16, suggesting that tumour-associated ...